LICENSE, COLLABORATION AND OTHER REVENUE - MTPC Collaboration Agreement - Narrative (Details)		3 Months Ended		9 Months Ended
	Dec. 11, 2015 USD ($) performance_obligation	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues		$ 37,428,000	$ 42,046,000	$ 113,683,000	$ 138,427,000
Accounts receivable, net		32,170,000		32,170,000		$ 39,290,000
Payables		13,494,000		13,494,000		$ 14,635,000
Revenue recognized		0	0	0	3,738,000
Mitsubishi Tanabe Pharma Corporation
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues	$ 6,400,000
Mitsubishi Tanabe Pharma Corporation | Royalty payments
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues		500,000	500,000	1,400,000	1,400,000
Mitsubishi Tanabe Pharma Corporation | Regulatory Milestone Payments
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone revenue	$ 25,000,000			25,000,000
Mitsubishi Tanabe Pharma Corporation | Development And Commercialize Collaboration Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of performance obligations | performance_obligation	2
Mitsubishi Tanabe Pharma Corporation | Development And Commercialize Research And License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront cash payment received	$ 20,000,000.0
Cost of research services	20,500,000
Milestone revenue	$ 10,000,000
Deferred revenue		0		0
Accounts receivable, net		0		0
Payables		0		0
Contract asset		500,000		500,000
Mitsubishi Tanabe Pharma Corporation | Mitsubishi Tanabe Pharma Corporation Supply Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Deferred revenue		0		0
Accounts receivable, net		0		0
Revenue recognized		0	$ 0	700,000	$ 3,700,000
Other liabilities, current		$ 0		$ 0